Artelo Biosciences (NASDAQ:ARTL) Raised to “Strong-Buy” at LADENBURG THALM/SH SH

Artelo Biosciences (NASDAQ:ARTL) was upgraded by LADENBURG THALM/SH SH to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other analysts also recently commented on the company. EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a report on Tuesday, October 1st. D. Boral Capital restated a “buy” rating and set a $6.00 price target on shares of Artelo Biosciences in a research note on Monday, December 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Artelo Biosciences in a research note on Monday, December 9th.

Artelo Biosciences Trading Up 1.4 %

Shares of NASDAQ:ARTL opened at $1.06 on Wednesday. The firm has a market cap of $3.42 million, a price-to-earnings ratio of -0.37 and a beta of 1.29. The stock’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $1.21. Artelo Biosciences has a 12-month low of $0.91 and a 12-month high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06. As a group, research analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.